Epigenetics Drugs And Diagnostic Technologies Market Share

Global Epigenetics Drugs And Diagnostic Technologies Market Report By Drugs Mechanism Of Action (DNMT Inhibitors And HDAC Inhibitors), Technology Type (DNA Methylation And Chromatin Immunoprecipitation (CHIP) Technology), And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2019-2026

ID:VMR11210484

February 2020

Report Formats:

Choose your Buying Option

Single User License: $ 3950.00

Upto 10 Users License: $ 4950.00

Enterprise License: $ 8600.00

Data Pack: $ 2100.00

Buy Now

Description
Table Of Content

As per this study the global epigenetics drugs and diagnostic technologies market was valued USD XX.X MN (by revenue) in 2019 and is anticipated to reach USD XX.X MN by 2026 with a CAGR of X.X%.

Epigenetics is a study of heritable changes in gene expression, it’s a change in phenotype without a change in genotype. Epigenetics drugs and diagnostic is used in screening of early stage cancer and other abnormal changes in skin cells, liver cells, brain cells, and others. It is caused by various factors such as aging and lifestyle changes along with environmental exposures.

Market Dynamics

The increasing geriatric population and rising oncology and non-oncology disorders are driving the market growth. Also, the high prevalence of cancer with advancement is screening techniques is further fuelling market growth. In addition, reduction in sequential cost and time is another factor pushing the market growth. Though, the funding and support of the organizations such as NIH and NCI for R&D are expected to boost the market growth in the forecast period. However, problems associated with quality may hamper market growth.

This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of epigenetics drugs and diagnostic technologies.

Market Segmentation

The broad epigenetics drugs and diagnostic technologies market has been sub-grouped into drugs mechanism of action and technology type. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.

By Drugs Mechanism Of Action

DNMT Inhibitors
- Azacitidine (Vidaza)
- Decitabine (Dacogen)
HDAC Inhibitors
- Vorinostat (Zolinza)
- Romidepsin (Istodax)

By Technology Types

DNA Methylation
Chromatin Immunoprecipitation (ChIP) Technology

Regional Analysis

Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for epigenetics drugs and diagnostic technologies in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.

Europe Epigenetics Drugs And Diagnostic Technologies Market By Revenue (USD MN)

The report also covers a detailed competitive landscape including company profiles of key players operating in the global market. The key players in the epigenetics drugs and diagnostic technologies market include 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., Celenge, CellCentric Ltd., Celleron Therapeutics Ltd., Chroma Therapeutics Ltd., Eisai Pharmaceuticals, EnVivo Pharmaceuticals Inc., Epigentek Group Inc., Epizyme, Inc. Illumina Inc., MDxHealth, Merck, Merck & Company Inc., Novartis International AG, Oncolys BioPharma Inc., Pharmacyclics, Promega Corporation, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Inc., Topotarget A/S, and Valirx Plc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.

METHODOLOGY:

A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY
       2.1. Highlights of Epigenetics Drugs And Diagnostic Technologies Market
       2.2. Global Epigenetics Drugs And Diagnostic Technologies Market Snapshot

3 . EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES – INDUSTRY ANALYSIS
       3.1. Introduction
       3.2. Market Drivers of Epigenetics Drugs And Diagnostic Technologies Market
       3.3. Market Restraints of Epigenetics Drugs And Diagnostic Technologies Market
       3.4. Opportunities of Epigenetics Drugs And Diagnostic Technologies Market
       3.5. Trends of Epigenetics Drugs And Diagnostic Technologies Market
       3.6. Porter’s Five Force Analysis of Epigenetics Drugs And Diagnostic Technologies Market
       3.7. Epigenetics Drugs And Diagnostic Technologies Market Attractiveness Analysis
           3.7.1 Market Attractive Analysis by Drugs Mechanism Of Action
           3.7.2 Market Attractive Analysis by Technology Types
           3.7.3 Market Attractive Analysis by Region

4 . VALUE CHAIN ANALYSIS
       4.1. Epigenetics Drugs And Diagnostic Technologies Value Chain Analysis
       4.2. Epigenetics Drugs And Diagnostic Technologies Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Epigenetics Drugs And Diagnostic Technologies Raw Material Manufactures List
           4.2.3. Price Trend of Epigenetics Drugs And Diagnostic Technologies Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend

5 . GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS BY DRUGS MECHANISM OF ACTION
       5.1 Overview by Drugs Mechanism Of Action
       5.2 Global Epigenetics Drugs And Diagnostic Technologies Market Analysis by Drugs Mechanism Of Action
       5.3 Market Analysis of DNMT Inhibitors by Regions
       5.4 Market Analysis of HDAC Inhibitors by Regions

6 . GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS BY TECHNOLOGY TYPES
       6.1 Overview by Technology Types
       6.2 Global Epigenetics Drugs And Diagnostic Technologies Market Analysis by Technology Types
       6.3 Market Analysis of DNA Methylation by Regions
       6.4 Market Analysis of Chromatin Immunoprecipitation (ChIP) Technology by Regions

7 . GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS BY GEOGRAPHY
       7.1. Regional Outlook
       7.2. Introduction
       7.3. North America
           7.3.1. Overview
           7.3.2. North America Epigenetics Drugs And Diagnostic Technologies Market Estimate by Market Segment
           7.3.3. North America Epigenetics Drugs And Diagnostic Technologies Market Estimate by Country
           7.3.4. United State
           7.3.5. Rest of North America
       7.4. Europe
           7.4.1. Overview
           7.4.2. Europe Epigenetics Drugs And Diagnostic Technologies Market Estimate by Market Segment
           7.4.3. Europe Epigenetics Drugs And Diagnostic Technologies Market Estimate by Country
           7.4.4. United Kingdom
           7.4.5. France
           7.4.6. Germany
           7.4.7 Rest of Europe
       7.5. Asia Pacific
           7.5.1. Overview
           7.5.2. Asia Pacific Epigenetics Drugs And Diagnostic Technologies Market Estimate by Market Segment
           7.5.3. Asia Pacific Epigenetics Drugs And Diagnostic Technologies Market Estimate by Country
           7.5.4. China
           7.5.5. Japan
           7.5.6. India
           7.5.7. Rest of Asia Pacific
       7.6. Latin America
           7.6.1. Overview
           7.6.2. Latin America Epigenetics Drugs And Diagnostic Technologies Market Estimate by Market Segment
           7.6.3. Latin America Epigenetics Drugs And Diagnostic Technologies Market Estimate by Country
           7.6.4. Brazil
           7.6.5. Rest of Latin America
       7.7. Middle East & Africa
           7.7.1. Overview
           7.7.2. Middle East & Africa Epigenetics Drugs And Diagnostic Technologies Market Estimate by Market Segment
           7.7.3. Middle East & Africa Epigenetics Drugs And Diagnostic Technologies Market Estimate by Country
           7.7.4. Middle East
           7.7.5. Africa

8 . COMPETITIVE LANDSCAPE OF THE EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES COMPANIES
       8.1. Epigenetics Drugs And Diagnostic Technologies Market Competition
       8.2. Partnership/Collaboration/Agreement
       8.3. Merger And Acquisitions
       8.4. New Product Launch
       8.5. Other Developments

9 . COMPANY PROFILES OF EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES INDUSTRY
       9.1. Company Share Analysis
       9.2. Market Concentration Rate
       9.3. 4SC AG
           9.3.1. Company Overview
           9.3.2. Financials
           9.3.3. Products
           9.3.4. Recent Developments
       9.4. Acetylon Pharmaceuticals, Inc.
           9.4.1. Company Overview
           9.4.2. Financials
           9.4.3. Products
           9.4.4. Recent Developments
       9.5. Astex Pharmaceuticals Inc.
           9.5.1. Company Overview
           9.5.2. Financials
           9.5.3. Products
           9.5.4. Recent Developments
       9.6. Celenge
           9.6.1. Company Overview
           9.6.2. Financials
           9.6.3. Products
           9.6.4. Recent Developments
       9.7. CellCentric Ltd.
           9.7.1. Company Overview
           9.7.2. Financials
           9.7.3. Products
           9.7.4. Recent Developments
       9.8. Celleron Therapeutics Ltd.
           9.8.1. Company Overview
           9.8.2. Financials
           9.8.3. Products
           9.8.4. Recent Developments
       9.9. Chroma Therapeutics Ltd.
           9.9.1. Company Overview
           9.9.2. Financials
           9.9.3. Products
           9.9.4. Recent Developments
       9.10. Eisai Pharmaceuticals
           9.10.1. Company Overview
           9.10.2. Financials
           9.10.3. Products
           9.10.4. Recent Developments
       9.11. EnVivo Pharmaceuticals Inc.
           9.11.1. Company Overview
           9.11.2. Financials
           9.11.3. Products
           9.11.4. Recent Developments
       9.12. Epigentek Group Inc.
           9.12.1. Company Overview
           9.12.2. Financials
           9.12.3. Products
           9.12.4. Recent Developments
       9.13. Epizyme, Inc. Illumina Inc.
           9.13.1. Company Overview
           9.13.2. Financials
           9.13.3. Products
           9.13.4. Recent Developments
       9.14. MDxHealth
           9.14.1. Company Overview
           9.14.2. Financials
           9.14.3. Products
           9.14.4. Recent Developments
       9.15. Merck
           9.15.1. Company Overview
           9.15.2. Financials
           9.15.3. Products
           9.15.4. Recent Developments
       9.16. Merck & Company Inc.
           9.16.1. Company Overview
           9.16.2. Financials
           9.16.3. Products
           9.16.4. Recent Developments
       9.17. Novartis International AG
           9.17.1. Company Overview
           9.17.2. Financials
           9.17.3. Products
           9.17.4. Recent Developments
       9.18. Oncolys BioPharma Inc.
           9.18.1. Company Overview
           9.18.2. Financials
           9.18.3. Products
           9.18.4. Recent Developments

10. IMPACT ANALYSIS OF COVID-19 OUTBREAK
10.1. Impact Analysis of Covid-19 Outbreak on the Market
10.1.1. Direct Impact on Production
10.1.2. Supply Chain and Market Disruption
10.1.3. Financial Impact on Firms and Financial Markets
10.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
10.3. Pre V/S Post COVID-19 Market
10.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Market Size in 2020, by Scenario
10.5. COVID-19: Micro and Macro Factor Analysis on the Market

*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

LIST OF FIGURES

Research Scope of Epigenetics Drugs And Diagnostic Technologies Report
Market Research Process
Market Research Methodology
Global Epigenetics Drugs And Diagnostic Technologies Market Size, by Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis by Drugs Mechanism Of Action
Market Attractiveness Analysis by Technology Types
Market Attractiveness Analysis by Region
Value Chain Analysis
Global Epigenetics Drugs And Diagnostic Technologies Market Analysis by Drugs Mechanism Of Action (USD MN)
Global Epigenetics Drugs And Diagnostic Technologies Market Analysis in DNMT Inhibitors by Geography (USD MN)
Global Epigenetics Drugs And Diagnostic Technologies Market Analysis in HDAC Inhibitors by Geography (USD MN)
Global Epigenetics Drugs And Diagnostic Technologies Market Analysis by Technology Types (USD MN)
Global Epigenetics Drugs And Diagnostic Technologies Market Analysis in DNA Methylation by Geography (USD MN)
Global Epigenetics Drugs And Diagnostic Technologies Market Analysis in Chromatin Immunoprecipitation (ChIP) Technology by Geography (USD MN)
Latin America Epigenetics Drugs And Diagnostic Technologies Market by Revenue
Middle East & Africa Epigenetics Drugs And Diagnostic Technologies Market by Revenue
Recent Development in Epigenetics Drugs And Diagnostic Technologies Industry
Company Market Share Analysis, 2019

* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Choose your Buying Option

Single User License: $ 3950.00

Upto 10 Users License: $ 4950.00

Enterprise License: $ 8600.00

Data Pack: $ 2100.00

Buy Now

Objectives of Study

Define and measure the global market
Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
Analyze and identify major market trends along with the factors driving or inhibiting the market growth
Study the company profiles of the major market players with their market share
Analyze competitive developments

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

Buy sections of this report
Buy country level reports
Request for historical data
Request discounts available for Start-Ups & Universities

Request for Special Pricing

Why Choose Us

Client First Policy

Excellent Quality

Robust After Sales Support

24/7 Email Support

Clients

Testimonials

" Doing business with Value Market Research was – quick, easy and accurate. We got what we expected. The team was very helpful and processes were altered for our convenience. The whole process from understanding our niche requirements to delivery to after sales was excellent. "

Vincenzo Baydar – Head Planning, Leading Food Chain, US

" Excellent work!! Working with you has been easy and direct. Your flexibility to alter the report scope and timely delivery assisted me in delivering my project proposal on time. "

Mia Tang, Director - Business Strategy, Steel Industry, Germany

" This is our second purchase and we have been obliged by the service. We appreciate the efforts put by Value Market Research in terms of understanding our needs, expanding the scope of the study, delivery and handling after sales queries. "

ID:VMR11210484

February 2020

Report Formats:

Choose your Buying Option

Choose your Buying Option

Objectives of Study

Buy Chapters or Sections

Why Choose Us

Client First Policy

Excellent Quality

Robust After Sales Support

24/7 Email Support

Clients

Testimonials

Vincenzo Baydar – Head Planning, Leading Food Chain, US

Mia Tang, Director - Business Strategy, Steel Industry, Germany

Jo Chin, Owner of a Manufacturing Plant in Taiwan

Key questions answered by the report

Need specific market information?

ID:VMR11210484

February 2020

Report Formats:

Choose your Buying Option

Choose your Buying Option

Objectives of Study

Buy Chapters or Sections

Why Choose Us

Client First Policy

Excellent Quality

Robust After Sales Support

24/7 Email Support

Clients

Testimonials

Vincenzo Baydar – Head Planning, Leading Food Chain, US

Mia Tang, Director - Business Strategy, Steel Industry, Germany

Jo Chin, Owner of a Manufacturing Plant in Taiwan

Key questions answered by the report

Need specific market information?

Important: Covid19 pandemic market impact